Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.67 |
| ▸ | PRNP | P04156 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | PPARG | P37231 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.63 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.63 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13701155 | 0.86 | KDM4E (0.71) | KDM4EALDH1A1FOLH1MCL1HPGD | |
| SCHEMBL29621784 | 0.84 | KDM4E (0.69) | KDM4EALDH1A1FOLH1MCL1HPGD | |
| SCHEMBL3205801 | 0.84 | KDM4E (0.69) | KDM4EALDH1A1FOLH1MCL1HPGD | |
| SCHEMBL9449744 | 0.83 | KDM4E (0.63) | KDM4EALDH1A1FOLH1CYP2C9CYP2C19 | |
| SCHEMBL3881052 | 0.83 | MCL1 (0.67) | KDM4EALDH1A1FOLH1MCL1HPGD | |
| SCHEMBL2002751 | 0.83 | FOLH1 (0.71) | KDM4EALDH1A1FOLH1MCL1HPGD | |
| SCHEMBL7463580 | 0.83 | KDM4E (0.71) | KDM4EALDH1A1FOLH1CYP2C9CYP2C19 | |
| SCHEMBL27616415 | 0.83 | KDM4E (0.67) | KDM4EALDH1A1FOLH1MCL1HPGD | |
| SCHEMBL1253451 | 0.82 | CNR1 (0.52) | KDM4EALDH1A1FOLH1CYP1A2CYP2C9 | |
| SCHEMBL7380594 | 0.82 | KDM4E (0.60) | KDM4EALDH1A1NPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4660193-A1 | INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024162746-A1 | INDOLE COMPOUND DECOMPOSING IKZF2, AND USE THEREOF | 한국화학연구원 | 2024-08-08 | — | — | WO | disclosed |
| EP-4363436-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2024-05-08 | — | — | EP | disclosed |
| CN-116829560-A | Oxytocin receptor modulators | 金奥克斯治疗有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-3298003-B1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2023-04-19 | — | — | EP | disclosed |
| WO-2023275357-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023275357-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2023-01-05 | — | — | WO | disclosed |
| EP-4112631-A1 | CASPASE-2 INHIBITOR COMPOUNDS | Kintsugi Therapeutics S.L. (ES) | 2023-01-04 | — | — | EP | disclosed |
| CN-107849015-B | Benzimidazole derivatives as PAD4 inhibitors | 葛兰素知识产权发展有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20200375946-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2020-12-03 | — | — | US | disclosed |
| US-20040147580-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2004-07-29 | — | — | US | disclosed |
| WO-2003088897-A2 | FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2003-10-30 | — | — | WO | disclosed |
| EP-1226138-A4 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1226138-A1 | FAB I INHIBITORS | SmithKline Beecham Corporation (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001027103-A1 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORPORATION (GB) | 2001-04-19 | — | — | WO | disclosed |
| US-6214856-B1 | TREATING NEURODEGENERATIVE DISORDERS, E.G., ALZHEIMER'S DISEASE, STROKES, TRAUMATIC BRAIN INJURY; ANTIISCHEMIC AGENTS; MUSCULAR DYSTROPHY; ALSO CATARACTS; PLATELET AGGREGATION | SMITHKLINE BEECHAM CORPORATION | 2001-04-10 | — | — | US | disclosed |
| EP-1018878-A4 | NOVEL INDOLECARBOXAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODSOF INHIBITING CALPAIN | SMITHKLINE BEECHAM CORP (US) | 2001-01-10 | — | — | EP | disclosed |
| EP-1018878-A1 | NOVEL INDOLECARBOXAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODSOF INHIBITING CALPAIN | SmithKline Beecham Corporation (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998041092-A1 | NOVEL INDOLECARBOXAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODSOF INHIBITING CALPAIN | SMITHKLINE BEECHAM CORPORATION (US) | 1998-09-24 | — | — | WO | disclosed |
| US-5523411-A | Synthesis of mitomycin and its analogs | RUTGERS UNIVERSITY (US) | 1996-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147580-A1 | Fab I inhibitors | SERPINB1, TMBIM6, GDI1 | KDM4E 4602/4885ALDH1A1 3962/4885FOLH1 2230/4885 |
| US-20200375946-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | IDO1, MGAM, LCT | KDM4E 1800/4885ALDH1A1 364/4885FOLH1 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.